E SWISS HLG MORE THAN NETWORKING

IS THE BIOPHARMA INDUSTRY SUSTAINABLE?

How partnering can help address geopolitical, environmental and pricing challenges.



Swiss HLG Conference 7th- 9th May, 2023

Grand Hotel Suisse Majestic, Montreux OPEN FOR REGISTRATION → www.swisshlg.com



Santen

U NOVARTIS

EIDEOGEN

SUBSTIPHARM

OM AJohmon INNOVATION

TILLOTTS PHARMA

(A) TRB

CONFRENCE PROGRAM

Sunday, May 7th 2023

Keynote

Patrick Aebischer, President Emeritus of EPFL

Keynote

Richard Bergström, Former EFPIA General Director

Monday, May 8th 2023

Session 1 - Pricing and affordability: The role of partnering to help address challenges and benefit society

Emerging from Disruption: Rethinking Pharma Michael Oberreiter, Head Global Access, F. Hoffmann-La Roche Ltd

Market access: moving from an adversarial to a collaborative relationship with healthcare systems

Neil Grubert, Independent Global Market Access Consultant, Trainer and Writer

Panel Discussion with Q&A: Pricing and affordability: The role of partnering to help address challenges and benefit society

Session 2 - Emerging and broken business models: Can partnering offer solutions?

The promise of cell & gene therapies – is the European healthcare system equipped to fairly value and pay for one-time, potentially curative treatments Oswald Bentinck, VP, Global Head - Value and Access at Rocket Pharmaceuticals

Anne Njis, Transformation Lead Rare Conditions, Roche

Tuesday, May 9th 2023

Session ${\bf 3}$ - How partnering enables the pharmaceutical sector to adapt to a changing and fragmenting world

Providing sustainability and resilience to the pharmaceutical value chain Viviane Monges, Chair of the Supervisory Board at EUROAPI

Jean Vielle, Global Head Transformation Novartis AG

The Global Fight against the Big Pandemics: A case study on Partnerships, Sustainability and Innovation

Lelio Marmora, CEO at The Management Lab

Closing Keynote

Lutz Hegemann, President Global Health & Sustainability at Novartis